• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Biocon Pharma gets GMP compliance certificate from MHRA, UK

expresspharmaApril 13, 2021

Tag: Biocon , MHRA , GMP

Biocon Pharma, a wholly-owned subsidiary of Biocon, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines & Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru.

“The certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, was issued based on a remote inspection in the week of March 22, 2021, in the wake of travel restrictions amidst COVID-19,” informed the company through a statement.

Previous:China mulls combining COVID-19 vaccines to enhance protection rate

Next:Sanofi and C4X Discovery enter licensing deal worth up to €414m

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Biocon Pharma gets GMP compliance certificate from MHRA, UK | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

99% up GMP DMF Colchicine 64-86-8

99% up GMP DMF Colchicine 64-86-8
99% up GMP DMF Ranolazine powder 95635-55-5

99% up GMP DMF Ranolazine powder 95635-55-5
99% up GMP DMF Hydroxynorephedrine/ metaraminol/ Benzenemethanol, a-[(1S)-1-aminoethyl]-3-hydroxy-,(

99% up GMP DMF Hydroxynorephedrine/ metaraminol/ Benzenemethanol, a-[(1S)-1-aminoethyl]-3-hydroxy-,(
99% up GMP DMF Rifaximin 80621-81-4

99% up GMP DMF Rifaximin 80621-81-4
99% up by HPLC GMP,DMF,CEP Gentamycin sulfate CAS NO.1405-41-0

99% up by HPLC GMP,DMF,CEP Gentamycin sulfate CAS NO.1405-41-0
99% up GMP DMF Ranitidine hydrochloride 66357-35-5

99% up GMP DMF Ranitidine hydrochloride 66357-35-5
99% up GMP DMF Famciclovir 104227-87-4

99% up GMP DMF Famciclovir 104227-87-4
PGZ (GMP) scraper bottom discharge automatic centrifuge

PGZ (GMP) scraper bottom discharge automatic centrifuge
pharmaceutical Oxytocin Acetate(GMP standard product) Peptide

pharmaceutical Oxytocin Acetate(GMP standard product) Peptide
99% up GMP DMF Loperamide 53179-11-6

99% up GMP DMF Loperamide 53179-11-6

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service